Having spent the past three months touting Sanofi's credentials as the pharma industry's leader in immunology R&D, CEO Paul Hudson has turned the spotlight on the French major's ability to launch products successfully, a position backed up by the stellar performance of the AstraZeneca PLC-partnered infant respiratory syncytial virus vaccine Beyfortus.
Presenting Sanofi's financials at its annual press conference in Paris, Hudson noted that the firm's key launches in 2023 –...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?